The U.S. Meals and Drug Administration (FDA) has permitted Journavx, a brand new ache reliever with out the dangers of dependancy or overdose linked to medication like Vicodin and OxyContin.
The brand new capsule, developed by Vertex Prescription drugs, is meant for short-term ache reduction following surgical procedure or damage, the Related Press reported.
Whereas it offers a long-awaited various to opioids and over-the-counter painkillers like ibuprofen, analysis suggests its effectiveness is modest in comparison with normal opioid remedies.
In contrast to opioids, which bind to mind receptors to cut back ache however usually result in dependence and dependancy, Journavx works otherwise.
The treatment blocks particular proteins that set off ache indicators earlier than they attain the mind.
“In trying to develop medicines that don’t have the addictive risks of opioid medicines, a key factor is working to block pain signaling before it gets to the brain,” Dr. David Altshuler, Vertex’s govt vice chairman and chief scientific officer, beforehand informed the Related Press.
Research of greater than 870 sufferers who took Journavx after foot and belly surgical procedure confirmed that the drug offered extra reduction than a placebo however was no more efficient than a standard opioid-acetaminophen mixture capsule.
“It’s not a slam dunk on effectiveness,” Michael Schuh of the Mayo Clinic, a pharmacist who was not concerned within the analysis, informed the Related Press. “But it is a slam dunk in that it’s a very different pathway and mechanism of action. So, I think that shows a lot promise.”
One main concern is price. Journavx could have an inventory value of $15.50 per capsule, in comparison with generic opioids, which price $1 or much less.
Some reported unwanted effects included nausea, constipation, itching, rash and headache, however no threat of dependancy.
“The new medication has side effect profiles that are inherently, not only different, but don’t involve the risk of substance abuse and other key side effects associated with opioids,” Dr. Charles Argoff of the Albany Medical Middle in New York, who consulted for Vertex on the drug’s improvement, informed the Related Press.
The approval marks the primary main development in ache therapy in additional than twenty years.
Vertex started creating the drug within the early 2000s, as opioid overdoses surged resulting from mass prescribing for power circumstances like arthritis and again ache.
Whereas opioid prescriptions have sharply declined in recent times, the present epidemic is generally fueled by illicit fentanyl, reasonably than pharmaceutical opioids, the Related Press reported.
Vertex has attracted a lot curiosity, however the drugmaker’s inventory took successful in December after disappointing ends in a examine of power nerve ache.
Regardless of this, the corporate plans to proceed with one other late-stage trial in hopes of getting FDA approval for power ache therapy.
Extra info:
The Cleveland Clinic has extra on dwelling with power ache.
© 2025 HealthDay. All rights reserved.
Quotation:
FDA approves first new non-opioid ache capsule in many years (2025, January 31)
retrieved 31 January 2025
from https://medicalxpress.com/information/2025-01-fda-opioid-pain-pill-decades.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
